You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Litigation Details for Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷  Sign Up , ⤷  Sign Up , and ⤷  Sign Up .

Details for Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 External link to document
2016-03-04 1 14. U.S. Patent Nos. 6,228,398 (“the ’398 patent”), 6,902,742 (“the ’742 patent”), …infringement of United States Patent No. 9,265,760 (“the ’760 patent”) under the Patent Laws of the United States…the ’760 patent under 28 U.S.C. §§ 2201 and 2202. A true and correct copy of the ’760 patent is attached…patients using a method of treatment patented by the ’760 patent prior to its expiration. 23.…patients using a method of treatment patented by the ’760 patent prior to its expiration. 25. External link to document
2018-03-16 112 17 and 19 of U.S. Patent No. 9,265,760 (“the ‘760 patent”) and claim 1 of U.S. Patent No. 9,339,499 (“…leading to the ‘499 patent was filed. (Ex. 2, ‘499 patent at face page.) The ‘499 patent is a continuation…of the ‘760 patent and the patents have near-identical specifications. The ‘499 patent issued on May…Asserted Claims are not patent eligible under the Supreme Court’s two-part test for patent-eligible subject …conventional. For example, each of the patent applications and patents disclosing hydrocodone ER dosage forms External link to document
2018-03-16 116 and 19 of U.S. Patent Nos. 9,265,760 (“the ’760 Patent”), and claim 1 of U.S. Patent No. 9,339,499 (“…the ’499 Patent”) (collectively, the “asserted claims” of the “patents-in- suit.”). The patents-in-suit… 1. Patent-Eligible Subject Matter Section 101 provides that a patent may be obtained…claims involve a patent-ineligible concept, because essentially every routinely patent-eligible claim … finding patents not invalid under § 101 as a matter of law). B. The patents-in-suit External link to document
2018-03-29 127 17 and 19 of U.S. Patent No. 9,265,760 (“the ’760 patent”), and claim 1 of U.S. Patent No. 9,339,499 (“…the ’499 patent”) (collectively, the “asserted claims” of the “patents-in- suit.”). The patents-in-suit…Infringement of ’760 Patent Claims 12, 17 and 19 and ’499 Patent Claim 1 ...........… infringe ’760 patent claims 12, 17 and 19 and ’499 patent claim 1.......…infringement of ’760 patent claims 12, 17 and 19 and ’499 patent claim 1 ...... External link to document
2018-04-06 139 and 19 of U.S. Patent Nos. 9,265,760 (“the ’760 Patent”), and claim 1 of U.S. Patent No. 9,339,499 (“…the ’499 Patent”) (collectively, the “asserted claims” of the “patents-in- suit.”). The patents-in-suit… 1. Patent-Eligible Subject Matter Section 101 provides that a patent may be obtained…claims involve a patent-ineligible concept, because essentially every routinely patent-eligible claim …............ 4 1. Patent-Eligible Subject Matter ....................... External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.